OCU410ST AAV5-hRORA Updated Nov 5
The next hard catalyst for OCU410ST is the Phase 2/3 GARDian3 topline data readout expected in Q2 2027 (roughly 5-7 months from now). If the 12-month data confirms the Phase 1 signal (54% lesion reduction, +6-letter BCVA gain), Ocugen plans a BLA submission by mid-2027, which would be a major revaluation event. If the data disappoints or shows no statistical separation, the stock could fall sharply given the 31.6% short interest. The DMC's recommendation to continue without modification after the interim analysis is mildly reassuring but not efficacy-confirming.
- No FDA-approved treatment exists for Stargardt disease, a rare inherited retinal condition affecting over 100,000 patients in the U.S. and EU, representing a large unmet medical need.
- Phase 1 GARDian1 data published in Nature Eye (Jan 2026) showed a 54% reduction in atrophic lesion growth in treated vs fellow eyes, +6-letter BCVA gain, and 48% slower lesion expansion with a favorable safety profile.
- Phase 2/3 GARDian3 enrollment and dosing completed early (63 patients in under 9 months), indicating strong patient and investigator demand.
- Very high short interest: 31.6% of outstanding shares short as of Oct 15, 2026, with 15.79 days to cover, reflecting heavy bearish positioning.
- CEO Shankar Musunuri sold approximately $1.0 million of stock in September and October 2026 via 10b5-1 plans at $0.95-$1.12 per share, well below the analyst mean price target.
- The Q3 2026 interim analysis was inconclusive: the DMC recommended continuing without modification, but management acknowledged small patient numbers, early 8-month timepoint, and heterogeneous baseline characteristics limited the readout.